Repligen Corporation (RGEN) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. At $131.37, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Expensive valuation; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2).
Repligen develops and commercializes bioprocessing products across four franchises—Filtration, Chromatography, Process Analytics, and Proteins—serving global biopharmaceutical manufacturers and CDMOs. Revenue is driven by consumable/single-use product sales with ~2,000 employees... Read more
Sell if holding. At $131.37, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Expensive valuation; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2). Chart setup: Death cross but MACD improving, RSI 76. Score 5.4/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 55d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-11Recent Developments — Repligen Corporation
Latest news
- NEWS Is Repligen Corp (RGEN) a Bargain After 3.7% Drop? GF Value Says Undervalued - GuruFocus — GuruFocus positive
- NEWS Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks - Yahoo Finance — Yahoo Finance neutral
- NEWS Repligen Corp (RGEN) Stock Up 4.2% and Still Undervalued -- GF S - GuruFocus — GuruFocus positive
- NEWS Repligen Corp (RGEN) Stock Down 5.8% -- Now Undervalued? GF Scor - GuruFocus — GuruFocus negative
- NEWS Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - StockStory — StockStory negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $131.37, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Expensive valuation; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2). Chart setup: Death cross but MACD improving, RSI 76. Prior stop was $121.61. Score 5.4/10, moderate confidence.
Take-profit target: $158.49 (+21.2% upside). Prior stop was $121.61. Stop-loss: $121.61.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Expensive valuation; Overbought (RSI 76).
Repligen Corporation trades at a P/E of 143.0 (forward 51.1). TrendMatrix value score: 3.6/10. Verdict: Sell.
28 analysts cover RGEN with a consensus score of 4.1/5. Average price target: $176.
What does Repligen Corporation do?Repligen develops and commercializes bioprocessing products across four franchises—Filtration, Chromatography, Process...
Repligen develops and commercializes bioprocessing products across four franchises—Filtration, Chromatography, Process Analytics, and Proteins—serving global biopharmaceutical manufacturers and CDMOs. Revenue is driven by consumable/single-use product sales with ~2,000 employees and manufacturing across the U.S., Europe, and Asia.